Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia

International Clinical Psychopharmacology

Volumn 17, Issue 2, 2002, Pages 59-64

  Shiloh, R ^a   Zemishlany, Z ^a   Aizenberg, D ^a   Valevski, A ^a   Bodinger, L ^a   Munitz, H ^a   Weizman, Abraham ^a  

^a GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Mianserin; Schizophrenia; Serotonin (5 HT) antagonist; Treatment resistant

Indexed keywords

CHLORPROMAZINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; MIANSERIN; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; SEROTONIN 2 ANTAGONIST; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0036186944     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200203000-00003     Document Type: Article

References (31)

1. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
2. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials
3. Options for the treatment of negative symptoms of schizophrenia
4. Risperidone versus other atypical antipsychotic medication for schizophrenia
5. Clozapine inhibits limbic system kindling: Implications for antipsychotic action
6. Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients
7. A rating scale for depression
8. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: An add-on, double-blind, placebo-controlled study
9. Typical and atypical neuroleptics stimulate contrasting patterns of neuropeptide and Fos/FRA expression in the striatum
10. Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: An open-label prospective pilot study
11. Clozapine for the treatment-resistant schizophrenic
12. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia
13. The Positive and Negative Symptom Scale (PANSS) for schizophrenia
14. A separate disease within the syndrome of schizophrenia
15. Experimental examination of trazodone
16. The mechanism of action of novel antipsychotic drugs
17. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs
18. Effects of mianserin in chronic schizophrenia
19. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
20. 2 adrenoreceptor antagonism account for the therapeutic advantage of new antipsychotics
21. The Brief Psychiatric Rating Scale
22. Treatment of neuroleptic-induced akathisia with the 5HT2 antagonist mianserin. Double-blind, placebo-controlled study
23. Preclinical pharmacology of neuroleptics: Focus on new generation compounds
24. Nefazodone in the adjunctive therapy of schizophrenia: An open-label exploratory study
25. Binding of typical and atypical antipsychotic agents to (5-hydroxytryptamine)6 and (5-hydroxytryptamine)7 receptors
26. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: A preliminary double-blind randomized placebo-controlled study
27. Antidepressant drugs. Comparative affinity for different receptors/transporters
28. Cyproheptadine treatment in neuroleptic-induced akathisia
29. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons